Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer
Moderate doses of bevacizumab and TAS-102 provided satisfactory efficacy over the standard dose within a limited timeframe of 9.5 months.
Authors
- Yu‐Zu Lin (ORCID: https://orcid.org/0000-0002-2504-2165)
- Jeng‐Kai Jiang (ORCID: https://orcid.org/0000-0001-8653-5476)
- Shih‐Ching Chang (ORCID: https://orcid.org/0000-0003-4947-2546)
- Hao‐Wei Teng (ORCID: https://orcid.org/0000-0001-8480-3422)
- Yuan‐Tzu Lan (ORCID: https://orcid.org/0000-0001-7350-6529)
- Hou-Hsuan Cheng
- Yi-Wen Yang (ORCID: https://orcid.org/0000-0002-6809-9081)
- Che-Yuan Chang
- Kuan-Yu Tseng (ORCID: https://orcid.org/0009-0004-4396-6056)
- Mu‐Ying Yang
- Chun-Chi Lin
- Wei-Shone Chen
- Sheng-Chieh Huang
- Huann-Sheng Wang
- Hung-Hsin Lin
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
Publication Details
- Journal
- International Journal of Colorectal Disease
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1007/s00384-024-04767-9
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taipei Veterans General Hospital